SEC Form 4 research
| Issuer | Aeglea BioTherapeutics, Inc. |
|---|---|
| Tickers | AGLE, SYRE |
| Reporting owners | 57 |
| Officers and directors | 17 |
| Last public filing | 2026-10-03 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-02 | 2026-10-01 | King-Jones Heidy | S | 2,600 | $93.46 | Not reported |
| 2026-10-02 | 2026-10-01 | King-Jones Heidy | S | 2,100 | $92.7 | Not reported |
| 2026-10-02 | 2026-10-01 | King-Jones Heidy | S | 7,228 | $91.35 | Not reported |
| 2026-10-02 | 2026-10-01 | King-Jones Heidy | S | 16,605 | $90.35 | Not reported |
| 2026-10-02 | 2026-10-01 | King-Jones Heidy | S | 400 | $89.24 | Not reported |
| 2026-10-02 | 2026-10-01 | Turtle Cameron | S | 100 | $93.91 | Not reported |
| 2026-10-02 | 2026-10-01 | Turtle Cameron | S | 4,990 | $93.37 | Not reported |
| 2026-10-02 | 2026-10-01 | Turtle Cameron | S | 3,989 | $92.31 | Not reported |
| 2026-10-02 | 2026-10-01 | Turtle Cameron | S | 2,638 | $91.49 | Not reported |
| 2026-10-02 | 2026-10-01 | Turtle Cameron | S | 2,683 | $90.1 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.